Anzeige
Mehr »
Login
Freitag, 25.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Vergiss die Indizes - Forge steigt um 40 %, während der S&P & Dow fällt!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EW0P | ISIN: US00808Y4061 | Ticker-Symbol: EJU0
Lang & Schwarz
25.04.25
07:00 Uhr
0,430 Euro
-0,430
-100,00 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
AETHLON MEDICAL INC Chart 1 Jahr
5-Tage-Chart
AETHLON MEDICAL INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,4200,44007:00

Aktuelle News zur AETHLON MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.03.AETHLON MEDICAL INC - 8-K, Current Report2
AETHLON MEDICAL Aktie jetzt für 0€ handeln
24.02.XFRA DIVERSE INSTRUMENTE: AUSSETZUNG/SUSPENSION1.191DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCASTOR MARITIME...
► Artikel lesen
13.02.Aethlon Medical strengthens oncology trial with protocol updates and cost reductions4
12.02.AETHLON MEDICAL INC - 10-Q, Quarterly Report-
12.02.AETHLON MEDICAL INC - 8-K, Current Report-
08.01.AETHLON MEDICAL INC - 8-K, Current Report13
20.12.24AETHLON MEDICAL INC - 8-K, Current Report18
15.11.24AETHLON MEDICAL INC - S-8, Securities to be offered to employees in employee benefit plans2
13.11.24AETHLON MEDICAL INC - 10-Q, Quarterly Report-
13.11.24Aethlon Medical, Inc.: Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update136Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid...
► Artikel lesen
12.11.24An Overview of Aethlon Medical's Earnings2
11.11.24Aethlon Medical, Inc.: Aethlon Medical Reaches Key Milestone with Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia187Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon's Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier®...
► Artikel lesen
14.08.24Aethlon Medical, Inc.: Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update190Received Two Australian Ethics Committee Approvals for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies...
► Artikel lesen
12.08.24Aethlon Medical, Inc.: Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial306Bellberry Human Research Ethics Committee Granted Full Ethics Approval to the Pindara Private Hospital for a Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with...
► Artikel lesen
27.06.24Aethlon Medical, Inc.: Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update259Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, June 27, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to...
► Artikel lesen
03.06.24Aethlon Medical, Inc.: Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies258Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo®...
► Artikel lesen
10.05.24Aethlon Medical, Inc.: Aethlon Medical Reports Positive Results From an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles From Cancer Patient Plasma193Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies Aethlon Medical...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1